

MODERNA INC.

ISIN: US60770K1079 WKN: 60770K107 Asset Class: **Stock**

Company

2022/10/05 22:00:00

moderna

Price

125.62

USD

Difference

-0.04%(-0.05)



Contact Details

MODERNA INC. Tel: 1-617-714-6500
 -- Fax: 617-583-1998
 200 Technology Square Web: <http://www.modernatx.com>
 02139 Cambridge E-mail: info@modernatx.com

Company Profile

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2021		2020		2019	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	16,071,000,000		6,297,879,000		1,128,804,000	
Common stock capital		0		40,000		34,000
Fixed assets	8,798,000,000		1,038,871,000		460,618,000	
Equity capital of a company		14,145,000,000		2,561,375,000		1,174,810,000
Cash and cash equivalents	6,848,000,000		2,624,882,000		236,908,000	
Accrued liabilities		0		0		0
Other assets	-		-		-	
Current liabilities		9,128,000,000		4,388,808,000		143,115,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		1,596,000,000		386,567,000		271,497,000
Different income		-		-		-
Other liabilities		691,000,000		179,272,000		139,133,000
Total assets	24,869,000,000	24,869,000,000	7,336,750,000	7,336,750,000	1,589,422,000	1,589,422,000

Balance notes

	2021	2020	2019
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	2,700	1,300	830
Equity ratio	56.88%	34.91%	73.91%
Debt-equity ratio	75.81%	186.44%	35.29%

Others

	2021	2020	2019
Tax Expense Rate	8.15%	-0.34%	0.14%

MODERNA INC.

ISIN: US60770K1079 WKN: 60770K107 Asset Class: Stock

Income statement

	2021	2020	2019
Turnover	18,413,000,000	803,395,000	60,209,000
Net income	12,202,000,000	-747,064,000	-514,021,000
EBIT	13,509,516,500	-772,174,880	-555,872,115
Operating income before taxes	13,285,000,000	-744,513,000	-514,716,000
Cash Flow	13,603,000,000	2,015,179,000	-470,644,000
Net interest income	0	14,829,000	31,918,000
Research and development expenses	1,759,000,000	1,339,088,000	465,288,000
Income taxes	1,083,000,000	2,551,000	-695,000
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	6,934,881	628,440	73,767

Board of Directors

Members of Management Board

Noubar Afeyan	Chairman of Board of Directors
Elizabeth Nabel	Member of Board of Directors
Francois Nader	Member of Board of Directors
Robert Langer	Member of Board of Directors
Sandra Horning	Member of Board of Directors
Elizabeth Tallett	Member of Board of Directors
Paul Sagan	Member of Board of Directors
Stephen Berenson	Member of Board of Directors
Stéphane Bancel	Chairman of Managing Board
Corinne Le Goff	Member of Executive Committee
David Meline	Member of Executive Committee
Juan Andres	Member of Executive Committee
Kate Cronin	Member of Executive Committee
Marcello Damiani	Member of Executive Committee
Paul Burton, M.D.	Member of Executive Committee
Shannon Thyme Klinger	Member of Executive Committee
Stephen Hoge, M.D.	Member of Executive Committee
Tracey Franklin	Member of Executive Committee